BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
31.19
+1.39 (4.66%)
At close: Jul 10, 2026
Market Cap13.57B -43.2%
Revenue (ttm)1.30B +9.1%
Net Income50.85M -63.2%
EPS0.12 -63.7%
Shares Out 435.23M
PE Ratio262.24
Forward PEn/a
Dividend0.02 (0.05%)
Ex-Dividend DateJun 9, 2026
Volume9,774,359
Open29.56
Previous Close29.80
Day's Range29.25 - 31.98
52-Week Range29.00 - 122.59
Beta0.25
Analystsn/a
Price Targetn/a
Earnings DateAug 31, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,196
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.

Financial Statements